FC
WST icon

Farringdon Capital’s West Pharmaceutical WST Stock Holding History

Farringdon Capital’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-966
Closed -$242K – 448
2026
Q1 		$242K Buy
+966
New +$240K 0.05% 323
2025
Q4 		– Sell
-799
Closed -$210K – 665
2025
Q3 		$210K Sell
799
-265
-25% -$64.4K 0.05% 396
2025
Q2 		$233K Buy
+1,064
New +$227K 0.08% 380

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Farringdon Capital's WST Position: Q2 2026 in Review

Farringdon Capital sold out of West Pharmaceutical (WST) in Q2 2026, closing a stake of 966 shares — an estimated $242K sold.

Farringdon Capital first reported a position in WST in Q2 2025 and held it in 3 quarters. The position peaked at $242K in Q1 2026. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Farringdon Capital reported no remaining West Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Farringdon Capital sold 966 West Pharmaceutical shares in Q2 2026, an estimated $242K.
  • Farringdon Capital first reported a position in West Pharmaceutical in Q2 2025 and held it in 3 quarters.
  • Farringdon Capital's West Pharmaceutical position peaked at $242K in Q1 2026.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Farringdon Capital's 13F filing for Q2 2026, filed 12 Aug 2026.